Drug Trial Radar · NCT07002177
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
196
Planned (sponsor's estimate)
Start
Jun 1, 2025
Primary completion
May 1, 2028
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- Forward Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer
Conditions
- Metastatic Breast Cancer
- Breast Cancer Stage I
- Breast Cancer Stage II
- Locally Advanced Breast Cancer (LABC)
- ER+ Breast Cancer
Interventions
FWD1802Drug
orally QD with 28 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons
Palbociclib 125mgDrug
Dose: 125 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break (3-weeks-on/1-week-off), constituting a 28-day cycle
Ribociclib 200Mg Oral TabletDrug
Dose: 600 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break, constituting a 28-day cycle
Abemaciclib 150 MGDrug
Dose: 150 mg Route: Orally Frequency: BID Schedule: Everyday
Everolimus 10 mgDrug
Dose: 10 mg Route: Orally Frequency: QD Schedule: Everyday
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib- Dose-Limiting Toxicity (DLT).Time frame: Approximately 1.5 years
- Phase Ib- Maximum Tolerated Dose (MTD).Time frame: Approximately 1.5 years
- Phase Ib- Recommended Phase II Dose (RP2D).Time frame: Approximately 1.5 years
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Approximately 2 years
- Severity Grading of Adverse EventsTime frame: Approximately 2 years
- Clinically Significant Abnormalities in 12-Lead ECG ParametersTime frame: Approximately 2 years
- Vital Sign AbnormalitiesTime frame: Approximately 2 years
- Serious Adverse Events (SAEs) IncidenceTime frame: Approximately 2 years
- Phase II- Investigator-assessed Objective Response Rate (ORR) based on RECIST v1.1.Time frame: Approximately 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center, Shanghai
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.